Physician profile
Tara Howell
NPI 1982874053
$2,754.21
in general payments reported to CMS, 2019-2025
26 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $55.57 · 2021: $372 · 2022: $372 · 2023: $712 · 2024: $363 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.21 | 2019-2025 | |
| Novo Nordisk INC | $440.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $293.78 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Merz North America, INC. | $286.05 | 2022-2023 | |
| Pfizer INC. | $162.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $108.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.63 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.82 | 2019-2021 | |
| Boston Scientific Corporation | $86.03 | 2025 | General - Pain Management |
| Amgen INC. | $64.46 | 2019-2025 | Repatha, Repatha, Otezla |
| Allergan, INC. | $56.11 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $52.94 | 2019 | |
| Galderma Laboratories, L.P. | $50.75 | 2022-2023 | Dysport |
| Amarin Pharma, INC. | $44.72 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.71 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.67 | 2019 | |
| Mylan Specialty L.P. | $32.85 | 2019 | |
| Idorsia Pharmaceuticals US INC | $30.64 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $29.41 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $21.62 | 2022 | |
| Horizon Therapeutics Plc | $19.66 | 2021 | |
| Genentech USA, INC. | $15.16 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.35 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.18 | 2019 | |
| Shire North American Group INC | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.